Dendreon Corp fka DNDNQ

[steveporsche]

DNDN Dendreon: Brean Murray continues to believe IMPACT will fail (6.83 ) <Courtesy of Nightowl on IV>

Brean Murray believes that the IMPACT trial will fail because it will be properly randomized and therefore will not be as imbalanced in its randomization as was the original D9901 trial. It is always easier to properly randomize larger trials than smaller trials, and IMPACT will enroll up to 500 patients, whereas D9901 enrolled 127 patients and D9902A enrolled 98 patients. 500 patients is also a more robust trial given its size -- a higher bar to hurdle. DNDN also amended its SPA to include all HRPC patients, regardless of Gleason score, providing an even more heterogeneous patient population and thus raising the bar even higher.